trial · primary record
Nipocalimab
Myasthenia Gravis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 115 |
| Primary completion | 2029-01-29 |
| Primary endpoint | Arms 1 and 2: Averaged Mean Percent Change from Baseline in Total Immunoglobulin G (IgG) Levels Over Weeks 8, 10 and 12 |
| Registry ID | NCT07217587 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:59:02.785Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07217587
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Nipocalimab · compound